{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T04:04:49Z","timestamp":1747541089735,"version":"3.40.5"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["P50HD103526","P50HD103526","P50HD103526","P50HD103526"],"award-info":[{"award-number":["P50HD103526","P50HD103526","P50HD103526","P50HD103526"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009726","name":"Foundation for Angelman Syndrome Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009726","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NINDS","award":["R01NS097808","R01NS097808"],"award-info":[{"award-number":["R01NS097808","R01NS097808"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Translational research is needed to discover pharmacological targets and treatments for the diagnostic behavioral domains of neurodevelopmental disorders (NDDs), including autism spectrum disorders (ASDs) and intellectual disabilities (IDs). One NDD, associated with ASD and ID, is Angelman Syndrome (AS). AS is a rare genetic NDD for which there is currently no cure nor effective therapeutics. The genetic cause is known to be the loss of expression from the maternal allele of ubiquitin protein ligase E3A (<jats:italic>UBE3A<\/jats:italic>). The <jats:italic>Ube3a<\/jats:italic> maternal deletion mouse model of AS reliably demonstrates behavioral phenotypes of relevance to AS and therefore offers a suitable in vivo system in which to test potential therapeutics, with construct and face validity. Successes in reducing hyperexcitability and epileptogenesis have been reported in an AS model following acute treatment with lovastatin, an ERK inhibitor by reducing seizure threshold and percentage of mice exhibiting seizures. Since there has been literature reporting disruption of the ERK signaling pathway in AS, we chose to evaluate the effects of acute lovastatin administration in a tailored set of translationally relevant behavioral assays in a mouse model of AS. Unexpectedly, deleterious effects of sedation were observed in wildtype (WT), age matched littermate control mice and despite a baseline hypolocomotive phenotype in AS mice, even further reductions in exploratory activity, were observed post-acute lovastatin treatment. Limitations of this work include that chronic lower dose regimens, more akin to drug administration in humans were beyond the scope of this work, and may have produced a more favorable impact of lovastatin administration over single acute high doses.\u00a0In addition, lovastatin\u2019s effects\u00a0were not assessed in younger subjects, since our study focused exclusively on adult functional outcomes. Metrics of gait, as well as motor coordination and motor learning in rotarod, previously observed to be impaired in AS mice, were not improved by lovastatin treatment. Finally, cognition by novel object recognition task was worsened in WT controls and not improved in AS, following lovastatin administration. In conclusion, lovastatin did not indicate any major improvement to AS symptoms, and in fact, worsened behavioral outcomes in the WT control groups. Therefore, despite its attractive low toxicity, immediate availability, and low cost of the drug, further investigation for clinical study is unwarranted given the results presented herein.<\/jats:p>","DOI":"10.1186\/s11689-025-09616-6","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:46:00Z","timestamp":1747471560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute administration of lovastatin had no pronounced effect on motor abilities, motor coordination, gait nor simple cognition in a mouse model of Angelman syndrome"],"prefix":"10.1186","volume":"17","author":[{"given":"Timothy A.","family":"Fenton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stela P.","family":"Petkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill L.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"issue":"7","key":"9616_CR1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/0883073809332767","volume":"24","author":"C Williams","year":"2009","unstructured":"Williams C. Angelman syndrome scientific symposium on the structure and function of UBE3A\/E6AP. J Child Neurol. 2009;24(7):904\u20138. https:\/\/doi.org\/10.1177\/0883073809332767. (PubMed PMID: 19617463).","journal-title":"J Child Neurol."},{"issue":"7380","key":"9616_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nature10784","volume":"481","author":"AL Beaudet","year":"2011","unstructured":"Beaudet AL. Angelman syndrome: Drugs to awaken a paternal gene. Nature. 2011;481(7380):150\u20132. Epub 20111221. https:\/\/doi.org\/10.1038\/nature10784. PubMed PMID: 22190038; PMCID: PMC3638729.","journal-title":"Nature"},{"issue":"10","key":"9616_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrneurol.2016.133","volume":"12","author":"K Buiting","year":"2016","unstructured":"Buiting K, Williams C, Horsthemke B. Angelman syndrome - insights into a rare neurogenetic disorder. Nat Rev Neurol. 2016;12(10):584\u201393. Epub 2016\/09\/13. https:\/\/doi.org\/10.1038\/nrneurol.2016.133. PubMed PMID: 27615419.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"9616_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s100480050034","volume":"1","author":"C Rougeulle","year":"1998","unstructured":"Rougeulle C, Lalande M. Angelman syndrome: how many genes to remain silent? Neurogenetics. 1998;1(4):229\u201337. https:\/\/doi.org\/10.1007\/s100480050034. PubMed PMID: 10732796.","journal-title":"Neurogenetics"},{"issue":"1","key":"9616_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/ng0997-14","volume":"17","author":"C Rougeulle","year":"1997","unstructured":"Rougeulle C, Glatt H, Lalande M. The Angelman syndrome candidate gene, UBE3A\/E6-AP, is imprinted in brain. Nat Genet. 1997;17(1):14\u20135. https:\/\/doi.org\/10.1038\/ng0997-14. PubMed PMID: 9288088.","journal-title":"Nat Genet"},{"issue":"1","key":"9616_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/ng0997-75","volume":"17","author":"U Albrecht","year":"1997","unstructured":"Albrecht U, Sutcliffe JS, Cattanach BM, Beechey CV, Armstrong D, Eichele G, Beaudet AL. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat Genet. 1997;17(1):75\u20138. https:\/\/doi.org\/10.1038\/ng0997-75. PubMed PMID: 9288101.","journal-title":"Nat Genet."},{"issue":"8","key":"9616_CR7","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1002\/cne.23507.PubMedPMID:24254964;PMCID:PMC3984624","volume":"522","author":"MC Judson","year":"2014","unstructured":"Judson MC, Sosa-Pagan JO, Del Cid WA, Han JE, Philpot BD. Allelic specificity of Ube3a expression in the mouse brain during postnatal development. J Comp Neurol. 2014;522(8):1874\u201396. https:\/\/doi.org\/10.1002\/cne.23507.PubMedPMID:24254964;PMCID:PMC3984624.","journal-title":"J Comp Neurol"},{"key":"9616_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13229-018-0238-0","volume":"9","author":"AC Burette","year":"2018","unstructured":"Burette AC, Judson MC, Li AN, Chang EF, Seeley WW, Philpot BD, Weinberg RJ. Subcellular organization of UBE3A in human cerebral cortex. Mol Autism. 2018;9:54. https:\/\/doi.org\/10.1186\/s13229-018-0238-0. Epub 20181019. PubMed PMID: 30364390; PMCID: PMC6194692.","journal-title":"Mol Autism."},{"issue":"2","key":"9616_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.braindev.2003.09.014","volume":"27","author":"CA Williams","year":"2005","unstructured":"Williams CA. Neurological aspects of the Angelman syndrome. Brain Dev. 2005;27(2):88\u201394. https:\/\/doi.org\/10.1016\/j.braindev.2003.09.014. PubMed PMID: 15668046.","journal-title":"Brain Dev"},{"issue":"4","key":"9616_CR10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/ajmg.c.30278","volume":"154C","author":"CA Williams","year":"2010","unstructured":"Williams CA. The behavioral phenotype of the Angelman syndrome. Am J Med Genet C Semin Med Genet. 2010;154C(4):432\u20137. https:\/\/doi.org\/10.1002\/ajmg.c.30278. PubMed PMID: 20981772.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"5","key":"9616_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ajmg.a.31074","volume":"140","author":"CA Williams","year":"2006","unstructured":"Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Laan LA, Magenis RE, Moncla A, Schinzel AA, Summers JA, Wagstaff J. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A. 2006;140(5):413\u20138. https:\/\/doi.org\/10.1002\/ajmg.a.31074. PubMed PMID: 16470747.","journal-title":"Am J Med Genet A"},{"issue":"7","key":"9616_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/GIM.0b013e3181def138","volume":"12","author":"CA Williams","year":"2010","unstructured":"Williams CA, Driscoll DJ, Dagli AI. Clinical and genetic aspects of Angelman syndrome. Genet Med. 2010;12(7):385\u201395. https:\/\/doi.org\/10.1097\/GIM.0b013e3181def138. PubMed PMID: 20445456.","journal-title":"Genet Med"},{"issue":"5","key":"9616_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2010.01.026","volume":"140","author":"PL Greer","year":"2010","unstructured":"Greer PL, Hanayama R, Bloodgood BL, Mardinly AR, Lipton DM, Flavell SW, Kim TK, Griffith EC, Waldon Z, Maehr R, Ploegh HL, Chowdhury S, Worley PF, Steen J, Greenberg ME. The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell. 2010;140(5):704\u201316. https:\/\/doi.org\/10.1016\/j.cell.2010.01.026. PubMedPMID:20211139;PMCID:PMC2843143.","journal-title":"Cell"},{"issue":"4","key":"9616_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/cpt.2543","volume":"111","author":"TR Flotte","year":"2022","unstructured":"Flotte TR, Gessler DJ. Gene Therapy for Rare Neurological Disorders. Clin Pharmacol Ther. 2022;111(4):743\u201357. https:\/\/doi.org\/10.1002\/cpt.2543. Epub 20220225.","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"9616_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/humc.2019.29049.int","volume":"30","author":"JM Wilson","year":"2019","unstructured":"Wilson JM. Breakthrough to Bedside: Bringing Gene Therapy to Neuromuscular Diseases. Hum Gene Ther Clin Dev. 2019;30(3):93\u20136. https:\/\/doi.org\/10.1089\/humc.2019.29049.int. Epub 20190910. PubMed PMID: 31486676.","journal-title":"Hum Gene Ther Clin Dev."},{"issue":"2","key":"9616_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/humc.2019.29046.int","volume":"30","author":"JM Wilson","year":"2019","unstructured":"Wilson JM. Cycling at the Frontiers of Gene Therapy. Hum Gene Ther Clin Dev. 2019;30(2):47\u20139. https:\/\/doi.org\/10.1089\/humc.2019.29046.int. PubMed PMID: 31215809.","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"7833","key":"9616_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41586-020-2835-2","volume":"587","author":"JM Wolter","year":"2020","unstructured":"Wolter JM, Mao H, Fragola G, Simon JM, Krantz JL, Bazick HO, Oztemiz B, Stein JL, Zylka MJ. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA. Nature. 2020;587(7833):281\u20134. https:\/\/doi.org\/10.1038\/s41586-020-2835-2. Epub 20201021. PubMed PMID: 33087932; PMCID: PMC8020672.","journal-title":"Nature."},{"issue":"12","key":"9616_CR18","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/hmg\/ddab104","volume":"30","author":"A Adhikari","year":"2021","unstructured":"Adhikari A, Copping NA, Beegle J, Cameron DL, Deng P, O\u2019Geen H, Segal DJ, Fink KD, Silverman JL, Anderson JS. Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells. Hum Mol Genet. 2021;30(12):1067\u201383. https:\/\/doi.org\/10.1093\/hmg\/ddab104. PubMedPMID:33856035;PMCID:PMC8188406 .","journal-title":"Hum Mol Genet"},{"issue":"3","key":"9616_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/mt.2015.236","volume":"24","author":"BJ Bailus","year":"2016","unstructured":"Bailus BJ, Pyles B, McAlister MM, O\u2019Geen H, Lockwood SH, Adams AN, Nguyen JT, Yu A, Berman RF, Segal DJ. Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain. Mol Ther. 2016;24(3):548\u201355. https:\/\/doi.org\/10.1038\/mt.2015.236. Epub 20160104. PubMed PMID: 26727042; PMCID: PMC4786922.","journal-title":"Mol Ther."},{"key":"9616_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1471-2202-15-76","volume":"15","author":"BJ Bailus","year":"2014","unstructured":"Bailus BJ, Segal DJ. The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders. BMC Neurosci. 2014;15:76. https:\/\/doi.org\/10.1186\/1471-2202-15-76. Epub 20140619. PubMed PMID: 24946931; PMCID: PMC4069279.","journal-title":"BMC Neurosci."},{"key":"9616_CR21","doi-asserted-by":"publisher","first-page":"789913","DOI":"10.3389\/fnmol.2021.789913","volume":"14","author":"P Deng","year":"2021","unstructured":"Deng P, Halmai J, Beitnere U, Cameron D, Martinez ML, Lee CC, Waldo JJ, Thongphanh K, Adhikari A, Copping N, Petkova SP, Lee RD, Lock S, Palomares M, O\u2019Geen H, Carter J, Gonzalez CE, Buchanan FKB, Anderson JD, Fierro FA, Nolta JA, Tarantal AF, Silverman JL, Segal DJ, Fink KD. An in vivo Cell-Based Delivery Platform for Zinc Finger Artificial Transcription Factors in Pre-clinical Animal Models. Front Mol Neurosci. 2021;14:789913. https:\/\/doi.org\/10.3389\/fnmol.2021.789913. Epub 20220127. PubMed PMID: 35153670; PMCID: PMC8829036.","journal-title":"Front Mol Neurosci."},{"issue":"4","key":"9616_CR22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ymthe.2023.01.013","volume":"31","author":"H O'Geen","year":"2023","unstructured":"O\u2019Geen H, Beitnere U, Garcia MS, Adhikari A, Cameron DL, Fenton TA, Copping NA, Deng P, Lock S, Halmai J, Villegas IJ, Liu J, Wang D, Fink KD, Silverman JL, Segal DJ. Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman Syndrome mouse model. Mol Ther. 2023;31(4):1088\u2013105. https:\/\/doi.org\/10.1016\/j.ymthe.2023.01.013. Epub 20230113. PubMed PMID: 36641623.","journal-title":"Mol Ther"},{"issue":"7539","key":"9616_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nature13975","volume":"518","author":"L Meng","year":"2015","unstructured":"Meng L, Ward AJ, Chun S, Bennett CF, Beaudet AL, Rigo F. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature. 2015;518(7539):409\u201312. https:\/\/doi.org\/10.1038\/nature13975. Epub 20141201. PubMed PMID: 25470045; PMCID: PMC4351819.","journal-title":"Nature."},{"key":"9616_CR24","doi-asserted-by":"publisher","unstructured":"Meng L, Person RE, Huang W, Zhu PJ, Costa-Mattioli M, Beaudet AL. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model. PLoS Genet. 2013;9(12). https:\/\/doi.org\/10.1371\/journal.pgen.1004039. Epub 20131226. PubMed PMID: 24385930; PMCID: PMC3873245.","DOI":"10.1371\/journal.pgen.1004039"},{"issue":"688","key":"9616_CR25","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1126\/scitranslmed.abf4077","volume":"15","author":"SV Dindot","year":"2023","unstructured":"Dindot SV, Christian S, Murphy WJ, Berent A, Panagoulias J, Schlafer A, Ballard J, Radeva K, Robinson R, Myers L, Jepp T, Shaheen H, Hillman P, Konganti K, Hillhouse A, Bredemeyer KR, Black L, Douville J, Consortium F, Consortium F. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript. Sci Transl Med. 2023;15(688):4077. https:\/\/doi.org\/10.1126\/scitranslmed.abf4077. Epub 20230322. PubMed PMID: 36947593.","journal-title":"Sci Transl Med"},{"issue":"1","key":"9616_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13229-021-00467-1","volume":"12","author":"EL Berg","year":"2021","unstructured":"Berg EL, Petkova SP, Born HA, Adhikari A, Anderson AE, Silverman JL. Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome. Mol Autism. 2021;12(1):59. https:\/\/doi.org\/10.1186\/s13229-021-00467-1. Epub 20210915. PubMed PMID: 34526125; PMCID: PMC8444390.","journal-title":"Mol Autism."},{"issue":"1","key":"9616_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/aur.2418","volume":"14","author":"E Cruz","year":"2021","unstructured":"Cruz E, Descalzi G, Steinmetz A, Scharfman HE, Katzman A, Alberini CM. CIM6P\/IGF-2 Receptor Ligands Reverse Deficits in Angelman Syndrome Model Mice. Autism Res. 2021;14(1):29\u201345. https:\/\/doi.org\/10.1002\/aur.2418. Epub 20201027. PubMed PMID: 33108069; PMCID: PMC8579913.","journal-title":"Autism Res."},{"key":"9616_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.nbd.2017.05.010","volume":"105","author":"I Jamal","year":"2017","unstructured":"Jamal I, Kumar V, Vatsa N, Shekhar S, Singh BK, Sharma A, Jana NR. Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome. Neurobiol Dis. 2017;105:99\u2013108. https:\/\/doi.org\/10.1016\/j.nbd.2017.05.010. Epub 20170530. PubMed PMID: 28576709.","journal-title":"Neurobiol Dis."},{"key":"9616_CR29","doi-asserted-by":"publisher","first-page":"3923384","DOI":"10.1155\/2022\/3923384","volume":"2022","author":"J Sun","year":"2022","unstructured":"Sun J, Liu Y, Hao X, Baudry M, Bi X. Lack of UBE3A-Mediated Regulation of Synaptic SK2 Channels Contributes to Learning and Memory Impairment in the Female Mouse Model of Angelman Syndrome. Neural Plast. 2022;2022:3923384. https:\/\/doi.org\/10.1155\/2022\/3923384. Epub 20221004. PubMed PMID: 36237484; PMCID: PMC9553421.","journal-title":"Neural Plast."},{"issue":"25","key":"9616_CR30","doi-asserted-by":"publisher","first-page":"12500","DOI":"10.1073\/pnas.1820131116","volume":"116","author":"J Wang","year":"2019","unstructured":"Wang J, Lou SS, Wang T, Wu RJ, Li G, Zhao M, Lu B, Li YY, Zhang J, Cheng X, Shen Y, Wang X, Zhu ZC, Li MJ, Takumi T, Yang H, Yu X, Liao L, Xiong ZQ. UBE3A-mediated PTPA ubiquitination and degradation regulate PP2A activity and dendritic spine morphology. Proc Natl Acad Sci U S A. 2019;116(25):12500\u20135. https:\/\/doi.org\/10.1073\/pnas.1820131116. Epub 20190603. PubMed PMID: 31160454; PMCID: PMC6589679.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"9616_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.nbd.2012.04.002","volume":"47","author":"M Baudry","year":"2012","unstructured":"Baudry M, Kramar E, Xu X, Zadran H, Moreno S, Lynch G, Gall C, Bi X. Ampakines promote spine actin polymerization, long-term potentiation, and learning in a mouse model of Angelman syndrome. Neurobiol Dis. 2012;47(2):210\u20135. https:\/\/doi.org\/10.1016\/j.nbd.2012.04.002. Epub 20120416. PubMed PMID: 22525571; PMCID: PMC3367059.","journal-title":"Neurobiol Dis."},{"issue":"2","key":"9616_CR32","doi-asserted-by":"publisher","first-page":"e1001478","DOI":"10.1371\/journal.pbio.1001478","volume":"11","author":"C Cao","year":"2013","unstructured":"Cao C, Rioult-Pedotti MS, Migani P, Yu CJ, Tiwari R, Parang K, Spaller MR, Goebel DJ, Marshall J. Impairment of TrkB-PSD-95 signaling in Angelman syndrome. PLoS Biol. 2013;11(2):e1001478. https:\/\/doi.org\/10.1371\/journal.pbio.1001478. Epub 20130212. PubMed PMID: 23424281; PMCID: PMC3570550.","journal-title":"PLoS Biol."},{"key":"9616_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuropharm.2018.10.038","volume":"144","author":"Y Liu","year":"2019","unstructured":"Liu Y, Johe K, Sun J, Hao X, Wang Y, Bi X, Baudry M. Enhancement of synaptic plasticity and reversal of impairments in motor and cognitive functions in a mouse model of Angelman Syndrome by a small neurogenic molecule, NSI-189. Neuropharmacology. 2019;144:337\u201344. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.10.038. Epub 20181105. PubMed PMID: 30408487.","journal-title":"Neuropharmacology."},{"key":"9616_CR34","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3389\/fnins.2019.00680","volume":"13","author":"FM Mouro","year":"2019","unstructured":"Mouro FM, Miranda-Lourenco C, Sebastiao AM, Diogenes MJ. From Cannabinoids and Neurosteroids to Statins and the Ketogenic Diet: New Therapeutic Avenues in Rett Syndrome? Front Neurosci. 2019;13:680. https:\/\/doi.org\/10.3389\/fnins.2019.00680. Epub 20190702. PubMed PMID: 31333401; PMCID: PMC6614559.","journal-title":"Front Neurosci."},{"key":"9616_CR35","doi-asserted-by":"publisher","unstructured":"Ottenhoff MJ, Krab LC, Elgersma Y. Considerations for Clinical Therapeutic Development of Statins for Neurodevelopmental Disorders. eNeuro. 2020;7(2)ENEURO.0392-19.2020.\u00a0https:\/\/doi.org\/10.1523\/ENEURO.0392-19.2020. Epub 20200306. PubMed PMID: 32071072; PMCID: PMC7070444.","DOI":"10.1523\/ENEURO.0392-19.2020"},{"issue":"1","key":"9616_CR36","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.biopsych.2022.11.016","volume":"94","author":"F Aria","year":"2023","unstructured":"Aria F, Pandey K, Alberini CM. Excessive Protein Accumulation and Impaired Autophagy in the Hippocampus of Angelman Syndrome Modeled in Mice. Biol Psychiatry. 2023;94(1):68\u201383. https:\/\/doi.org\/10.1016\/j.biopsych.2022.11.016. Epub 20221205. PubMed PMID: 36764852; PMCID: PMC10276539.","journal-title":"Biol Psychiatry."},{"key":"9616_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.nbd.2017.10.016","volume":"110","author":"L Chung","year":"2018","unstructured":"Chung L, Bey AL, Towers AJ, Cao X, Kim IH, Jiang YH. Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model. Neurobiol Dis. 2018;110:12\u20139. https:\/\/doi.org\/10.1016\/j.nbd.2017.10.016. Epub 20171031. PubMed PMID: 29097328; PMCID: PMC5903876.","journal-title":"Neurobiol Dis."},{"key":"9616_CR38","doi-asserted-by":"publisher","unstructured":"Muscas M, Seo SS, Louros SR, Osterweil EK. A Differential Effect of Lovastatin versus Simvastatin in Neurodevelopmental Disorders. eNeuro. 2020;7(4):ENEURO.0162-20.2020. https:\/\/doi.org\/10.1523\/ENEURO.0162-20.2020. Epub 20200813. PubMed PMID: 32651266; PMCID: PMC7433894.","DOI":"10.1523\/ENEURO.0162-20.2020"},{"key":"9616_CR39","doi-asserted-by":"publisher","unstructured":"Muscas M, Louros SR, Osterweil EK. Lovastatin, not Simvastatin, Corrects Core Phenotypes in the Fragile X Mouse Model. eNeuro. 2019;6(3):ENEURO.0097-19.2019. https:\/\/doi.org\/10.1523\/ENEURO.0097-19.2019. Epub 20190612. PubMed PMID: 31147392; PMCID: PMC6565377.","DOI":"10.1523\/ENEURO.0097-19.2019"},{"issue":"2","key":"9616_CR40","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.neuron.2012.01.034","volume":"77","author":"EK Osterweil","year":"2013","unstructured":"Osterweil EK, Chuang SC, Chubykin AA, Sidorov M, Bianchi R, Wong RK, Bear MF. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron. 2013;77(2):243\u201350. https:\/\/doi.org\/10.1016\/j.neuron.2012.01.034. PubMedPMID:23352161;PMCID:PMC3597444.","journal-title":"Neuron"},{"issue":"6","key":"9616_CR41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/1354750X.2016.1160289","volume":"21","author":"D Pellerin","year":"2016","unstructured":"Pellerin D, Caku A, Fradet M, Bouvier P, Dube J, Corbin F. Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet\u2019s signaling cascades as new outcome measures in clinical trials. Biomarkers. 2016;21(6):497\u2013508. https:\/\/doi.org\/10.3109\/1354750X.2016.1160289. Epub 20160408. PubMed PMID: 27058300.","journal-title":"Biomarkers."},{"issue":"494","key":"9616_CR42","doi-asserted-by":"publisher","first-page":"eaao0498","DOI":"10.1126\/scitranslmed.aao0498","volume":"11","author":"A Asiminas","year":"2019","unstructured":"Asiminas A, Jackson AD, Louros SR, Till SM, Spano T, Dando O, Bear MF, Chattarji S, Hardingham GE, Osterweil EK, Wyllie DJA, Wood ER, Kind PC. Sustained correction of associative learning deficits after brief, early treatment in a rat model of Fragile X Syndrome. Sci Transl Med. 2019;11(494):eaao0498. https:\/\/doi.org\/10.1126\/scitranslmed.aao0498. PubMed PMID: 31142675; PMCID: PMC8162683.","journal-title":"Sci Transl Med."},{"issue":"42","key":"9616_CR43","doi-asserted-by":"publisher","first-page":"8801","DOI":"10.1523\/JNEUROSCI.0925-21.2021","volume":"41","author":"EL Berg","year":"2021","unstructured":"Berg EL, Jami SA, Petkova SP, Berz A, Fenton TA, Lerch JP, Segal DJ, Gray JA, Ellegood J, Wohr M, Silverman JL. Excessive Laughter-like Vocalizations, Microcephaly, and Translational Outcomes in the Ube3a Deletion Rat Model of Angelman Syndrome. J Neurosci. 2021;41(42):8801\u201314. https:\/\/doi.org\/10.1523\/JNEUROSCI.0925-21.2021. Epub 20210902. PubMed PMID: 34475199; PMCID: PMC8528495.","journal-title":"J Neurosci"},{"key":"9616_CR44","doi-asserted-by":"publisher","unstructured":"Berg EL, Pride MC, Petkova SP, Lee RD, Copping NA, Shen Y, Adhikari A, Fenton TA, Pedersen LR, Noakes LS, Nieman BJ, Lerch JP, Harris S, Born HA, Peters MM, Deng P, Cameron DL, Fink KD, Beitnere U, O'Geen H, Anderson AE, Dindot SV, Nash KR, Weeber EJ, Wohr M, Ellegood J, Segal DJ, Silverman JL. Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome. Transl Psychiatry. 2020;10(1):39. Epub 2020\/02\/19. https:\/\/doi.org\/10.1038\/s41398-020-0720-2. PubMed PMID: 32066685; PMCID: PMC7026078.","DOI":"10.1038\/s41398-020-0720-2"},{"key":"9616_CR45","doi-asserted-by":"publisher","unstructured":"Born HA, Martinez LA, Levine AT, Harris SE, Mehra S, Lee WL, Dindot SV, Nash KR, Silverman JL, Segal DJ, Weeber EJ, Anderson AE. Early Developmental EEG and Seizure Phenotypes in a Full Gene Deletion of Ubiquitin Protein Ligase E3A Rat Model of Angelman Syndrome. eNeuro. 2021;8(2). Epub 20210324. https:\/\/doi.org\/10.1523\/ENEURO.0345-20.2020. PubMed PMID: 33531368; PMCID: PMC8114899.","DOI":"10.1523\/ENEURO.0345-20.2020"},{"key":"9616_CR46","doi-asserted-by":"publisher","unstructured":"Copping NA, Silverman JL. Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome. Mol Autism. 2021;12(1):9. Epub 2021\/02\/08. https:\/\/doi.org\/10.1186\/s13229-021-00416-y. PubMed PMID: 33549123; PMCID: PMC7866697.","DOI":"10.1186\/s13229-021-00416-y"},{"key":"9616_CR47","doi-asserted-by":"publisher","unstructured":"Petkova SP, Adhikari A, Berg EL, Fenton TA, Duis J, Silverman JL. Gait as a quantitative translational outcome measure in Angelman syndrome. Autism Res. 2022;15(5):821\u201333. Epub 20220310. https:\/\/doi.org\/10.1002\/aur.2697. PubMed PMID: 35274462; PMCID: PMC9311146.","DOI":"10.1002\/aur.2697"},{"key":"9616_CR48","doi-asserted-by":"publisher","unstructured":"Mainberger F, Langer S, Mall V, Jung NH. Impaired synaptic plasticity in RASopathies: a mini-review. J Neural Transm (Vienna). 2016;123(10):1133\u20138. Epub 20160826. https:\/\/doi.org\/10.1007\/s00702-016-1609-3. PubMed PMID: 27565148.","DOI":"10.1007\/s00702-016-1609-3"},{"key":"9616_CR49","doi-asserted-by":"publisher","unstructured":"Copping NA, Christian SGB, Ritter DJ, Islam MS, Buscher N, Zolkowska D, Pride MC, Berg EL, LaSalle JM, Ellegood J, Lerch JP, Reiter LT, Silverman JL, Dindot SV. Neuronal overexpression of Ube3a isoform 2 causes behavioral impairments and neuroanatomical pathology relevant to 15q11.2-q13.3 duplication syndrome. Hum Mol Genet. 2017;26(20):3995\u20134010. https:\/\/doi.org\/10.1093\/hmg\/ddx289. PubMed PMID: 29016856; PMCID: PMC5886211.","DOI":"10.1093\/hmg\/ddx289"},{"key":"9616_CR50","doi-asserted-by":"publisher","unstructured":"Tomaszewski M, Zolkowska D, Plewa Z, Czuczwar SJ, Luszczki JJ. Effect of acute and chronic exposure to lovastatin on the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol. 2021;907:174290. Epub 20210701. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174290. PubMed PMID: 34217711.","DOI":"10.1016\/j.ejphar.2021.174290"},{"key":"9616_CR51","doi-asserted-by":"publisher","unstructured":"Zhu Y, D'Agostino J, Zhang QY. Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse. Drug Metab Dispos. 2011;39(6):939\u201343. Epub 20110224. https:\/\/doi.org\/10.1124\/dmd.110.037861. PubMed PMID: 21349922; PMCID: PMC3100899.","DOI":"10.1124\/dmd.110.037861"},{"key":"9616_CR52","doi-asserted-by":"publisher","unstructured":"Silverman JL, Crawley JN. The promising trajectory of autism therapeutics discovery. Drug Discov Today. 2014;19(7):838\u201344. Epub 20131218. https:\/\/doi.org\/10.1016\/j.drudis.2013.12.007. PubMed PMID: 24362109.","DOI":"10.1016\/j.drudis.2013.12.007"},{"key":"9616_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/7854_2015_5003.PubMedPMID:27305922;PMCID:PMC5116923","volume":"28","author":"TM Kazdoba","year":"2016","unstructured":"Kazdoba TM, Leach PT, Yang M, Silverman JL, Solomon M, Crawley JN. Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics. Curr Top Behav Neurosci. 2016;28:1\u201352. https:\/\/doi.org\/10.1007\/7854_2015_5003.PubMedPMID:27305922;PMCID:PMC5116923.","journal-title":"Curr Top Behav Neurosci"},{"key":"9616_CR54","doi-asserted-by":"publisher","unstructured":"Silverman JL, Nithianantharajah J, Der-Avakian A, Young JW, Sukoff Rizzo SJ. Lost in translation: At the crossroads of face validity and translational utility of behavioral assays in animal models for the development of therapeutics. Neurosci Biobehav Rev. 2020;116:452\u20133. Epub 2020\/07\/19. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.07.008. PubMed PMID: 32681939.","DOI":"10.1016\/j.neubiorev.2020.07.008"},{"key":"9616_CR55","doi-asserted-by":"publisher","unstructured":"Sukoff Rizzo SJ, Silverman JL. Methodological Considerations for Optimizing and Validating Behavioral Assays. Curr Protoc Mouse Biol. 2016;6(4):364\u201379. Epub 20161201. https:\/\/doi.org\/10.1002\/cpmo.17. PubMed PMID: 27906464; PMCID: PMC6054129.","DOI":"10.1002\/cpmo.17"},{"key":"9616_CR56","doi-asserted-by":"publisher","unstructured":"Sukoff Rizzo SJ, Homanics G, Schaeffer DJ, Schaeffer L, Park JE, Oluoch J, Zhang T, Haber A, Seyfried NT, Paten B, Greenwood A, Murai T, Choi SH, Huhe H, Kofler J, Strick PL, Carter GW, Silva AC. Bridging the rodent to human translational gap: Marmosets as model systems for the study of Alzheimer's disease. Alzheimers Dement (N Y). 2023;9(3):e12417. Epub 20230821. https:\/\/doi.org\/10.1002\/trc2.12417. PubMed PMID: 37614242; PMCID: PMC10442521.","DOI":"10.1002\/trc2.12417"},{"key":"9616_CR57","doi-asserted-by":"publisher","unstructured":"Sukoff Rizzo SJ. The essential role of animal models in the advancement of our understanding of human behaviors: A Commentary on the Special issue on the 30th Anniversary of the International Behavioral Neuroscience Society (IBNS). Neurosci Biobehav Rev. 2023;149:105182. Epub 20230417. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105182. PubMed PMID: 37076055.","DOI":"10.1016\/j.neubiorev.2023.105182"},{"key":"9616_CR58","doi-asserted-by":"publisher","unstructured":"Sukoff Rizzo SJ, Masters A, Onos KD, Quinney S, Sasner M, Oblak A, Lamb BT, Territo PR, consortium M-A. Improving preclinical to clinical translation in Alzheimer's disease research. Alzheimers Dement (N Y). 2020;6(1):e12038. Epub 20200614. https:\/\/doi.org\/10.1002\/trc2.12038. PubMed PMID: 32548237; PMCID: PMC7293992.","DOI":"10.1002\/trc2.12038"},{"key":"9616_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/164_2019_282","volume":"257","author":"SJ Sukoff Rizzo","year":"2020","unstructured":"Sukoff Rizzo SJ, McTighe S, McKinzie DL. Genetic Background and Sex: Impact on Generalizability of Research Findings in Pharmacology Studies. Handb Exp Pharmacol. 2020;257:147\u201362. https:\/\/doi.org\/10.1007\/164_2019_282. PubMed PMID: 31595415.","journal-title":"Handb Exp Pharmacol"},{"key":"9616_CR60","doi-asserted-by":"publisher","unstructured":"Sukoff Rizzo SJ, Anderson LC, Green TL, McGarr T, Wells G, Winter SS. Assessing Healthspan and Lifespan Measures in Aging Mice: Optimization of Testing Protocols, Replicability, and Rater Reliability. Curr Protoc Mouse Biol. 2018;8(2):e45. Epub 2018\/06\/21. https:\/\/doi.org\/10.1002\/cpmo.45. PubMed PMID: 29924918.","DOI":"10.1002\/cpmo.45"},{"key":"9616_CR61","doi-asserted-by":"publisher","unstructured":"Dodge A, Peters MM, Greene HE, Dietrick C, Botelho R, Chung D, Willman J, Nenninger AW, Ciarlone S, Kamath SG, Houdek P, Sumova A, Anderson AE, Dindot SV, Berg EL, O'Geen H, Segal DJ, Silverman JL, Weeber EJ, Nash KR. Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion. Autism Res. 2020;13(3):397\u2013409. Epub 20200121. https:\/\/doi.org\/10.1002\/aur.2267. PubMed PMID: 31961493; PMCID: PMC7787396.","DOI":"10.1002\/aur.2267"},{"key":"9616_CR62","doi-asserted-by":"publisher","unstructured":"Leach PT, Hayes J, Pride M, Silverman JL, Crawley JN. Normal Performance of Fmr1 Mice on a Touchscreen Delayed Nonmatching to Position Working Memory Task. eNeuro. 2016;3(1). Epub 20160315. https:\/\/doi.org\/10.1523\/ENEURO.0143-15.2016. PubMed PMID: 27022628; PMCID: PMC4800045.","DOI":"10.1523\/ENEURO.0143-15.2016"},{"key":"9616_CR63","doi-asserted-by":"publisher","unstructured":"Sidorov MS, Judson MC, Kim H, Rougie M, Ferrer AI, Nikolova VD, Riddick NV, Moy SS, Philpot BD. Enhanced Operant Extinction and Prefrontal Excitability in a Mouse Model of Angelman Syndrome. J Neurosci. 2018;38(11):2671\u201382. Epub 20180205. https:\/\/doi.org\/10.1523\/JNEUROSCI.2828-17.2018. PubMed PMID: 29431654; PMCID: PMC5852653.","DOI":"10.1523\/JNEUROSCI.2828-17.2018"},{"issue":"12","key":"9616_CR64","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1172\/JCI130419.PubMedPMID:31503547;PMCID:PMC6877312","volume":"129","author":"B Gu","year":"2019","unstructured":"Gu B, Zhu M, Glass MR, Rougie M, Nikolova VD, Moy SS, Carney PR, Philpot BD. Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice. J Clin Invest. 2019;129(12):5462\u20137. https:\/\/doi.org\/10.1172\/JCI130419.PubMedPMID:31503547;PMCID:PMC6877312.","journal-title":"J Clin Invest"},{"key":"9616_CR65","doi-asserted-by":"publisher","unstructured":"Huang HS, Burns AJ, Nonneman RJ, Baker LK, Riddick NV, Nikolova VD, Riday TT, Yashiro K, Philpot BD, Moy SS. Behavioral deficits in an Angelman syndrome model: effects of genetic background and age. Behav Brain Res. 2013;243:79\u201390. Epub 20130104. https:\/\/doi.org\/10.1016\/j.bbr.2012.12.052. PubMed PMID: 23295389; PMCID: PMC3629944.","DOI":"10.1016\/j.bbr.2012.12.052"},{"key":"9616_CR66","doi-asserted-by":"publisher","unstructured":"Martinez LA, Born HA, Harris S, Regnier-Golanov A, Grieco JC, Weeber EJ, Anderson AE. Quantitative EEG Analysis in Angelman Syndrome: Candidate Method for Assessing Therapeutics. Clin EEG Neurosci. 2020:1550059420973095. Epub 20201118. https:\/\/doi.org\/10.1177\/1550059420973095. PubMed PMID: 33203220.","DOI":"10.1177\/1550059420973095"},{"issue":"21","key":"9616_CR67","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.cub.2005.09.043","volume":"15","author":"W Li","year":"2005","unstructured":"Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol. 2005;15(21):1961\u20137. https:\/\/doi.org\/10.1016\/j.cub.2005.09.043. PubMed PMID: 16271875.","journal-title":"Curr Biol"},{"key":"9616_CR68","doi-asserted-by":"publisher","unstructured":"Chen Y, Li LB, Zhang J, Tang DP, Wei JJ, Zhuang ZH. Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study. Lipids Health Dis. 2018;17(1):290. Epub 20181222. https:\/\/doi.org\/10.1186\/s12944-018-0946-7. PubMed PMID: 30579354; PMCID: PMC6303879.","DOI":"10.1186\/s12944-018-0946-7"},{"key":"9616_CR69","doi-asserted-by":"publisher","unstructured":"Ongerth T, Russmann V, Fischborn S, Boes K, Siegl C, Potschka H. Targeting of microglial KCa3.1 channels by TRAM-34 exacerbates hippocampal neurodegeneration and does not affect ictogenesis and epileptogenesis in chronic temporal lobe epilepsy models. Eur J Pharmacol. 2014;740:72\u201380. Epub 20140710. https:\/\/doi.org\/10.1016\/j.ejphar.2014.06.061. PubMed PMID: 25016931.","DOI":"10.1016\/j.ejphar.2014.06.061"},{"key":"9616_CR70","doi-asserted-by":"publisher","unstructured":"Glaser N, Chu S, Weiner J, Zdepski L, Wulff H, Tancredi D, ME OD. Effects of TRAM-34 and minocycline on neuroinflammation caused by diabetic ketoacidosis in a rat model. BMJ Open Diabetes Res Care. 2022;10(3). https:\/\/doi.org\/10.1136\/bmjdrc-2022-002777. PubMed PMID: 35584854; PMCID: PMC9119135.","DOI":"10.1136\/bmjdrc-2022-002777"},{"key":"9616_CR71","doi-asserted-by":"publisher","unstructured":"Glaser N, Little C, Lo W, Cohen M, Tancredi D, Wulff H, O'Donnell M. Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain. Pediatr Diabetes. 2017;18(5):356\u201366. Epub 20160513. https:\/\/doi.org\/10.1111\/pedi.12396. PubMed PMID: 27174668.","DOI":"10.1111\/pedi.12396"},{"key":"9616_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13229-017-0142-z.PubMedPMID:28638591;PMCID:PMC5472997","volume":"8","author":"SC Dhamne","year":"2017","unstructured":"Dhamne SC, Silverman JL, Super CE, Lammers SHT, Hameed MQ, Modi ME, Copping NA, Pride MC, Smith DG, Rotenberg A, Crawley JN, Sahin M. Replicable in vivo physiological and behavioral phenotypes of the Shank3B null mutant mouse model of autism. Mol Autism. 2017;8:26. https:\/\/doi.org\/10.1186\/s13229-017-0142-z.PubMedPMID:28638591;PMCID:PMC5472997.","journal-title":"Mol Autism"},{"key":"9616_CR73","doi-asserted-by":"publisher","unstructured":"Gompers AL, Su-Feher L, Ellegood J, Copping NA, Riyadh MA, Stradleigh TW, Pride MC, Schaffler MD, Wade AA, Catta-Preta R, Zdilar I, Louis S, Kaushik G, Mannion BJ, Plajzer-Frick I, Afzal V, Visel A, Pennacchio LA, Dickel DE, Lerch JP, Crawley JN, Zarbalis KS, Silverman JL, Nord AS. Germline Chd8 haploinsufficiency alters brain development in mouse. Nat Neurosci. 2017;20(8):1062\u201373. Epub 20170626. https:\/\/doi.org\/10.1038\/nn.4592. PubMed PMID: 28671691; PMCID: PMC6008102.","DOI":"10.1038\/nn.4592"},{"key":"9616_CR74","doi-asserted-by":"publisher","unstructured":"Haigh JL, Adhikari A, Copping NA, Stradleigh T, Wade AA, Catta-Preta R, Su-Feher L, Zdilar I, Morse S, Fenton TA, Nguyen A, Quintero D, Agezew S, Sramek M, Kreun EJ, Carter J, Gompers A, Lambert JT, Canales CP, Pennacchio LA, Visel A, Dickel DE, Silverman JL, Nord AS. Deletion of a non-canonical regulatory sequence causes loss of Scn1a expression and epileptic phenotypes in mice. Genome Med. 2021;13(1):69. Epub 20210426. https:\/\/doi.org\/10.1186\/s13073-021-00884-0. PubMed PMID: 33910599; PMCID: PMC8080386.","DOI":"10.1186\/s13073-021-00884-0"},{"key":"9616_CR75","doi-asserted-by":"publisher","unstructured":"Silverman JL, Fenton T, Haouchine O, Hallam E, Smith E, Jackson K, Rahbarian D, Canales C, Adhikari A, Nord A, Ben-Shalom R. Hyperexcitability and translational phenotypes in a preclinical model of SYNGAP1 mutations. Res Sq. 2023. Epub 20230913. https:\/\/doi.org\/10.21203\/rs.3.rs-3246655\/v1. PubMed PMID: 37790402; PMCID: PMC10543290.","DOI":"10.21203\/rs.3.rs-3246655\/v1"},{"key":"9616_CR76","doi-asserted-by":"publisher","unstructured":"Silverman JL, Pride MC, Hayes JE, Puhger KR, Butler-Struben HM, Baker S, Crawley JN. GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism. Neuropsychopharmacology. 2015;40(9):2228\u201339. Epub 20150310. https:\/\/doi.org\/10.1038\/npp.2015.66. PubMed PMID: 25754761; PMCID: PMC4613612.","DOI":"10.1038\/npp.2015.66"},{"key":"9616_CR77","doi-asserted-by":"publisher","unstructured":"Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, Bryce DK, Smith DL, Fonseca K, Ring RH, Crawley JN. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med. 2012;4(131):131ra51. https:\/\/doi.org\/10.1126\/scitranslmed.3003501. PubMed PMID: 22539775; PMCID: PMC4904784.","DOI":"10.1126\/scitranslmed.3003501"},{"issue":"18","key":"9616_CR78","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1093\/hmg\/ddac091.PubMedPMID:35445702;PMCID:PMC9476626","volume":"31","author":"A Adhikari","year":"2022","unstructured":"Adhikari A, Buchanan FKB, Fenton TA, Cameron DL, Halmai J, Copping NA, Fink KD, Silverman JL. Touchscreen cognitive deficits, hyperexcitability and hyperactivity in males and females using two models of Cdkl5 deficiency. Hum Mol Genet. 2022;31(18):3032\u201350. https:\/\/doi.org\/10.1093\/hmg\/ddac091.PubMedPMID:35445702;PMCID:PMC9476626.","journal-title":"Hum Mol Genet"},{"key":"9616_CR79","doi-asserted-by":"publisher","unstructured":"Fenton TA, Haouchine OY, Hallam EL, Smith EM, Jackson KC, Rahbarian D, Canales C, Adhikari A, Nord AS, Ben-Shalom R, Silverman JL. Hyperexcitability and translational phenotypes in a preclinical model of SYNGAP1 mutations. bioRxiv. 2023. Epub 20230726. https:\/\/doi.org\/10.1101\/2023.07.24.550093. PubMed PMID: 37546838; PMCID: PMC10402099.","DOI":"10.1101\/2023.07.24.550093"},{"issue":"5","key":"9616_CR80","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.neubiorev.2004.06.006","volume":"28","author":"RN Hughes","year":"2004","unstructured":"Hughes RN. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci Biobehav Rev. 2004;28(5):497\u2013505. https:\/\/doi.org\/10.1016\/j.neubiorev.2004.06.006. PubMed PMID: 15465137.","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"9616_CR81","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0091-3057(76)90081-2","volume":"5","author":"L Kokkinidis","year":"1976","unstructured":"Kokkinidis L, Anisman H. Dissociation of the effects of scopolamine and d-amphetamine on a spontaneous alternation task. Pharmacol Biochem Behav. 1976;5(3):293\u20137. https:\/\/doi.org\/10.1016\/0091-3057(76)90081-2. PubMed PMID: 996062.","journal-title":"Pharmacol Biochem Behav"},{"key":"9616_CR82","doi-asserted-by":"publisher","unstructured":"Prieur EAK, Jadavji NM. Assessing Spatial Working Memory Using the Spontaneous Alternation Y-maze Test in Aged Male Mice. Bio Protoc. 2019;9(3):e3162. Epub 20190205. https:\/\/doi.org\/10.21769\/BioProtoc.3162. PubMed PMID: 33654968; PMCID: PMC7854095.","DOI":"10.21769\/BioProtoc.3162"},{"issue":"12","key":"9616_CR83","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/s0531-5565(02)00123-7","volume":"37","author":"R Lalonde","year":"2002","unstructured":"Lalonde R, Dumont M, Fukuchi K, Strazielle C. Transgenic mice expressing the human C99 terminal fragment of betaAPP: effects on spatial learning, exploration, anxiety, and motor coordination. Exp Gerontol. 2002;37(12):1401\u201312. https:\/\/doi.org\/10.1016\/s0531-5565(02)00123-7. PubMed PMID: 12559409.","journal-title":"Exp Gerontol"},{"key":"9616_CR84","doi-asserted-by":"publisher","unstructured":"Lainiola M, Procaccini C, Linden AM. mGluR3 knockout mice show a working memory defect and an enhanced response to MK-801 in the T- and Y-maze cognitive tests. Behav Brain Res. 2014;266:94\u2013103. Epub 20140311. https:\/\/doi.org\/10.1016\/j.bbr.2014.03.008. PubMed PMID: 24631392.","DOI":"10.1016\/j.bbr.2014.03.008"},{"key":"9616_CR85","doi-asserted-by":"publisher","unstructured":"Kim J, Kang H, Lee YB, Lee B, Lee D. A quantitative analysis of spontaneous alternation behaviors on a Y-maze reveals adverse effects of acute social isolation on spatial working memory. Sci Rep. 2023;13(1):14722. Epub 20230907. https:\/\/doi.org\/10.1038\/s41598-023-41996-4. PubMed PMID: 37679447; PMCID: PMC10485067.","DOI":"10.1038\/s41598-023-41996-4"},{"key":"9616_CR86","doi-asserted-by":"publisher","unstructured":"Gulinello M, Mitchell HA, Chang Q, Timothy O'Brien W, Zhou Z, Abel T, Wang L, Corbin JG, Veeraragavan S, Samaco RC, Andrews NA, Fagiolini M, Cole TB, Burbacher TM, Crawley JN. Rigor and reproducibility in rodent behavioral research. Neurobiol Learn Mem. 2019;165:106780. Epub 20180104. https:\/\/doi.org\/10.1016\/j.nlm.2018.01.001. PubMed PMID: 29307548; PMCID: PMC6034984.","DOI":"10.1016\/j.nlm.2018.01.001"},{"key":"9616_CR87","doi-asserted-by":"publisher","unstructured":"Grieco JC, Gouelle A, Weeber EJ. Identification of spatiotemporal gait parameters and pressure-related characteristics in children with Angelman syndrome: A pilot study. J Appl Res Intellect Disabil. 2018;31(6):1219\u201324. Epub 20180508. https:\/\/doi.org\/10.1111\/jar.12462. PubMed PMID: 29737626.","DOI":"10.1111\/jar.12462"},{"key":"9616_CR88","doi-asserted-by":"publisher","unstructured":"Duis J, Nespeca M, Summers J, Bird L, Bindels-de Heus K, Valstar MJ, de Wit MY, Navis C, Ten Hooven-Radstaake M, van Iperen-Kolk BM, Ernst S, Dendrinos M, Katz T, Diaz-Medina G, Katyayan A, Nangia S, Thibert R, Glaze D, Keary C, Pelc K, Simon N, Sadhwani A, Heussler H, Wheeler A, Woeber C, DeRamus M, Thomas A, Kertcher E, DeValk L, Kalemeris K, Arps K, Baym C, Harris N, Gorham JP, Bohnsack BL, Chambers RC, Harris S, Chambers HG, Okoniewski K, Jalazo ER, Berent A, Bacino CA, Williams C, Anderson A. A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome. Mol Genet Genomic Med. 2022;10(3):e1843. Epub 20220211. https:\/\/doi.org\/10.1002\/mgg3.1843. PubMed PMID: 35150089; PMCID: PMC8922964.","DOI":"10.1002\/mgg3.1843"},{"key":"9616_CR89","doi-asserted-by":"publisher","unstructured":"Duis J, Skinner A, Carson R, Gouelle A, Annoussamy M, Silverman JL, Apkon S, Servais L, Carollo J. Quantitative measures of motor development in Angelman syndrome. Am J Med Genet A. 2023;191(7):1711\u201321. Epub 20230405. https:\/\/doi.org\/10.1002\/ajmg.a.63192. PubMed PMID: 37019838.","DOI":"10.1002\/ajmg.a.63192"},{"key":"9616_CR90","doi-asserted-by":"publisher","unstructured":"Bird LM, Tan WH, Bacino CA, Peters SU, Skinner SA, Anselm I, Barbieri-Welge R, Bauer-Carlin A, Gentile JK, Glaze DG, Horowitz LT, Mohan KN, Nespeca MP, Sahoo T, Sarco D, Waisbren SE, Beaudet AL. A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome. Am J Med Genet A. 2011;155A(12):2956\u201363. Epub 20111014. https:\/\/doi.org\/10.1002\/ajmg.a.34297. PubMed PMID: 22002941; PMCID: PMC3222728.","DOI":"10.1002\/ajmg.a.34297"},{"key":"9616_CR91","doi-asserted-by":"publisher","unstructured":"Ciarlone SL, Grieco JC, D'Agostino DP, Weeber EJ. Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model. Neurobiol Dis. 2016;96:38\u201346. Epub 20160818. https:\/\/doi.org\/10.1016\/j.nbd.2016.08.002. PubMed PMID: 27546058.","DOI":"10.1016\/j.nbd.2016.08.002"},{"key":"9616_CR92","doi-asserted-by":"publisher","unstructured":"Ciarlone SL, Wang X, Rogawski MA, Weeber EJ. Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model. Neuropharmacology. 2017;116:142\u201350. Epub 20161213. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.12.009. PubMed PMID: 27986596.","DOI":"10.1016\/j.neuropharm.2016.12.009"},{"key":"9616_CR93","doi-asserted-by":"crossref","unstructured":"Adikari, Copping, J B, D C, KD F, JL S, JD A. Functional rescue in an Angelman syndrome model following treatment with lentivector transduced hematopoietic stem cells. Hum Gene Ther. 2021;In Press.","DOI":"10.1093\/hmg\/ddab104"},{"key":"9616_CR94","doi-asserted-by":"publisher","unstructured":"Leach PT, Crawley JN. Touchscreen learning deficits in Ube3a, Ts65Dn and Mecp2 mouse models of neurodevelopmental disorders with intellectual disabilities. Genes Brain Behav. 2018;17(6):e12452. Epub 2017\/12\/22. https:\/\/doi.org\/10.1111\/gbb.12452. PubMed PMID: 29266714; PMCID: PMC6013336.","DOI":"10.1111\/gbb.12452"},{"key":"9616_CR95","doi-asserted-by":"publisher","unstructured":"Grieco JC, Bahr RH, Schoenberg MR, Conover L, Mackie LN, Weeber EJ. Quantitative Measurement of Communication Ability in Children with Angelman Syndrome. J Appl Res Intellect Disabil. 2018;31(1):e49-e58. Epub 20161219. https:\/\/doi.org\/10.1111\/jar.12305. PubMed PMID: 27990716.","DOI":"10.1111\/jar.12305"},{"key":"9616_CR96","doi-asserted-by":"publisher","unstructured":"Akula SK, McCullough KB, Weichselbaum C, Dougherty JD, Maloney SE. The trajectory of gait development in mice. Brain Behav. 2020;10(6):e01636. Epub 20200424. https:\/\/doi.org\/10.1002\/brb3.1636. PubMed PMID: 32333523; PMCID: PMC7303394.","DOI":"10.1002\/brb3.1636"},{"issue":"8","key":"9616_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.220.PubMedPMID:34370398;PMCID:PMC8363132","volume":"1","author":"JM Garrick","year":"2021","unstructured":"Garrick JM, Costa LG, Cole TB, Marsillach J. Evaluating Gait and Locomotion in Rodents with the CatWalk. Curr Protoc. 2021;1(8): e220. https:\/\/doi.org\/10.1002\/cpz1.220.PubMedPMID:34370398;PMCID:PMC8363132.","journal-title":"Curr Protoc"},{"key":"9616_CR98","doi-asserted-by":"publisher","unstructured":"Matas E, Maisterrena A, Thabault M, Balado E, Francheteau M, Balbous A, Galvan L, Jaber M. Major motor and gait deficits with sexual dimorphism in a Shank3 mutant mouse model. Mol Autism. 2021;12(1):2. Epub 20210119. https:\/\/doi.org\/10.1186\/s13229-020-00412-8. PubMed PMID: 33468258; PMCID: PMC7814442.","DOI":"10.1186\/s13229-020-00412-8"},{"key":"9616_CR99","doi-asserted-by":"publisher","unstructured":"Rahn RM, Weichselbaum CT, Gutmann DH, Dougherty JD, Maloney SE. Shared developmental gait disruptions across two mouse models of neurodevelopmental disorders. J Neurodev Disord. 2021;13(1):10. Epub 20210320. https:\/\/doi.org\/10.1186\/s11689-021-09359-0. PubMed PMID: 33743598; PMCID: PMC7980331.","DOI":"10.1186\/s11689-021-09359-0"},{"issue":"7","key":"9616_CR100","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/DBP.0b013e3181ee408e.PubMedPMID:20729760;PMCID:PMC2997715","volume":"31","author":"JK Gentile","year":"2010","unstructured":"Gentile JK, Tan WH, Horowitz LT, Bacino CA, Skinner SA, Barbieri-Welge R, Bauer-Carlin A, Beaudet AL, Bichell TJ, Lee HS, Sahoo T, Waisbren SE, Bird LM, Peters SU. A neurodevelopmental survey of Angelman syndrome with genotype-phenotype correlations. J Dev Behav Pediatr. 2010;31(7):592\u2013601. https:\/\/doi.org\/10.1097\/DBP.0b013e3181ee408e.PubMedPMID:20729760;PMCID:PMC2997715.","journal-title":"J Dev Behav Pediatr"},{"issue":"1","key":"9616_CR101","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ajmg.a.33775.PubMedPMID:21204213;PMCID:PMC3563320","volume":"155A","author":"WH Tan","year":"2011","unstructured":"Tan WH, Bacino CA, Skinner SA, Anselm I, Barbieri-Welge R, Bauer-Carlin A, Beaudet AL, Bichell TJ, Gentile JK, Glaze DG, Horowitz LT, Kothare SV, Lee HS, Nespeca MP, Peters SU, Sahoo T, Sarco D, Waisbren SE, Bird LM. Angelman syndrome: Mutations influence features in early childhood. Am J Med Genet A. 2011;155A(1):81\u201390. https:\/\/doi.org\/10.1002\/ajmg.a.33775.PubMedPMID:21204213;PMCID:PMC3563320.","journal-title":"Am J Med Genet A"},{"key":"9616_CR102","doi-asserted-by":"publisher","unstructured":"Mabb AM, Judson MC, Zylka MJ, Philpot BD. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. Trends Neurosci. 2011;34(6):293\u2013303. Epub 20110517. https:\/\/doi.org\/10.1016\/j.tins.2011.04.001. PubMed PMID: 21592595; PMCID: PMC3116240.","DOI":"10.1016\/j.tins.2011.04.001"},{"key":"9616_CR103","doi-asserted-by":"publisher","unstructured":"Lee HM, Clark EP, Kuijer MB, Cushman M, Pommier Y, Philpot BD. Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome. Mol Autism. 2018;9:45. Epub 2018\/08\/25. https:\/\/doi.org\/10.1186\/s13229-018-0228-2. PubMed PMID: 30140420; PMCID: PMC6098585.","DOI":"10.1186\/s13229-018-0228-2"},{"key":"9616_CR104","doi-asserted-by":"publisher","unstructured":"Kumar V, Joshi T, Vatsa N, Singh BK, Jana NR. Simvastatin Restores HDAC1\/2 Activity and Improves Behavioral Deficits in Angelman Syndrome Model Mouse. Front Mol Neurosci. 2019;12:289. Epub 20191126. https:\/\/doi.org\/10.3389\/fnmol.2019.00289. PubMed PMID: 31849603; PMCID: PMC6901934.","DOI":"10.3389\/fnmol.2019.00289"},{"issue":"4","key":"9616_CR105","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.pediatrneurol.2011.06.016","volume":"45","author":"MT Acosta","year":"2011","unstructured":"Acosta MT, Kardel PG, Walsh KS, Rosenbaum KN, Gioia GA, Packer RJ. Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study. Pediatr Neurol. 2011;45(4):241\u20135. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2011.06.016. PubMed PMID: 21907886.","journal-title":"Pediatr Neurol"},{"key":"9616_CR106","doi-asserted-by":"publisher","unstructured":"Bearden CE, Hellemann GS, Rosser T, Montojo C, Jonas R, Enrique N, Pacheco L, Hussain SA, Wu JY, Ho JS, McGough JJ, Sugar CA, Silva AJ. A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I. Ann Clin Transl Neurol. 2016;3(4):266\u201379. Epub 20160222. https:\/\/doi.org\/10.1002\/acn3.288. PubMed PMID: 27081657; PMCID: PMC4818747.","DOI":"10.1002\/acn3.288"},{"key":"9616_CR107","doi-asserted-by":"publisher","unstructured":"Payne JM, Barton B, Ullrich NJ, Cantor A, Hearps SJ, Cutter G, Rosser T, Walsh KS, Gioia GA, Wolters PL, Tonsgard J, Schorry E, Viskochil D, Klesse L, Fisher M, Gutmann DH, Silva AJ, Hunter SJ, Rey-Casserly C, Cantor NL, Byars AW, Stavinoha PL, Ackerson JD, Armstrong CL, Isenberg J, O'Neil SH, Packer RJ, Korf B, Acosta MT, North KN, Consortium NFCT. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016;87(24):2575\u201384. Epub 20161109. https:\/\/doi.org\/10.1212\/WNL.0000000000003435. PubMed PMID: 27956565; PMCID: PMC5207004.","DOI":"10.1212\/WNL.0000000000003435"},{"key":"9616_CR108","doi-asserted-by":"publisher","unstructured":"Thurman AJ, Potter LA, Kim K, Tassone F, Banasik A, Potter SN, Bullard L, Nguyen V, McDuffie A, Hagerman R, Abbeduto L. Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome. J Neurodev Disord. 2020;12(1):12. Epub 20200422. https:\/\/doi.org\/10.1186\/s11689-020-09315-4. PubMed PMID: 32316911; PMCID: PMC7175541.","DOI":"10.1186\/s11689-020-09315-4"},{"key":"9616_CR109","doi-asserted-by":"publisher","unstructured":"Caku A, Pellerin D, Bouvier P, Riou E, Corbin F. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study. Am J Med Genet A. 2014;164A(11):2834\u201342. Epub 20140924. https:\/\/doi.org\/10.1002\/ajmg.a.36750. PubMed PMID: 25258112.","DOI":"10.1002\/ajmg.a.36750"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11689-025-09616-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T08:46:03Z","timestamp":1747471563000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-025-09616-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9616"],"URL":"https:\/\/doi.org\/10.1186\/s11689-025-09616-6","relation":{},"ISSN":["1866-1955"],"issn-type":[{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following IACUC was reviewed and approved by the UC Davis IACUC on April 20, 2023. Active protocols are reviewed annually.Title: Novel Testing of Therapeutics for Angelman Syndrome. Principal Investigator: Jill L. SilvermanProtocol #: 23384Institution: University of California, DavisThis institution is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International (AAALAC). This institution has an Animal Welfare Assurance on file with the Office of Laboratory Animal Welfare (OLAW). The Assurance Number is D16-00272 (A3433-01). The IACUC is constituted in accordance with U.S. Public Health Service (PHS) Animal Welfare Policy and includes a member of the public and a non-scientist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"FAST, the MIND Institute and the NIH\/NICHD IDDRC consent for the data presented herein to be publishable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}